Cilengitide trifluoroacetate

For research use only. Not for use in humans.

目录号:S7077 别名: EMD 121974, NSC 707544 中文名称:三氟醋酸盐西仑吉肽

Cilengitide trifluoroacetate Chemical Structure

CAS No. 199807-35-7

Cilengitide (EMD 121974, NSC 707544)是一种有效的integrin抑制剂,作用于αvβ3受体和αvβ5受体,无细胞试验中IC50分别为4.1 nM和79 nM,比作用于gpIIbIIIa选择性高10倍左右。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 3718.02 现货
RMB 2212.59 现货
RMB 8108.38 现货
有超大折扣
今日订购,明日送达 全国免运费 分装免费
全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Cilengitide trifluoroacetate发表文献54篇:

产品安全说明书

Integrin抑制剂选择性比较

生物活性

产品描述 Cilengitide (EMD 121974, NSC 707544)是一种有效的integrin抑制剂,作用于αvβ3受体和αvβ5受体,无细胞试验中IC50分别为4.1 nM和79 nM,比作用于gpIIbIIIa选择性高10倍左右。Phase 2。
靶点
αvβ3 receptor [1]
(Cell-free assay)
αvβ5 receptor [2]
(Cell-free assay)
4.1 nM 79 nM
体外研究

Cilengitide是一种环化五胜肽类肽,争夺精氨酸-甘氨酸-天冬氨酸(RGD)肽序列。调节整合素-配体结合。Cilengitide选择性且有效抑制αvβ3和αvβ5整合素与基质蛋白结合,如Vitronectin, Fibronectin, Fibrinogen, von Willebrand Factor, Osteopontin, 及其他。[1]10 μM Cilengitide完全抑制BAE,BME和HUVE细胞与Vitronectin 和 Fibronectin附着。Cilengitide在体外作用于三维胶原蛋白和血纤维蛋白凝胶使用FGF-2(或 VEGF-A)预处理的BAE细胞,抑制血管生成,IC50分别为15 μM 和8 μM, 4 μM 和 3 μM。[2]Cilengitide 抑制细胞增殖,诱导内皮细胞凋亡,且诱导人体内皮前体细胞分化。50 μg/mL Cilengitide完全抑制人体微血管内皮细胞系HMEC-1增殖,导致〜30%细胞发生细胞凋亡。[3]1 μM Cilengitide处理9天,抑制近40%EPCs增殖。1 μM Cilengitide处理14天,抑制80%以上EPCs 分化。[4]Cilengitide抑制粘附,诱导肿瘤细胞凋亡。25 μg/mL Cilengitide使60%以上的DAOY细胞(髓母细胞瘤)和U87MG细胞(胶质母细胞瘤) 与Vitronectin 和 Tenascin分离。25 μg/mL Cilengitide诱导细胞凋亡率将近50% 。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
G28 M{\oWGZ2dmO2aX;uJGF{e2G7 MnzlOVAh|rypL33s MkDpN|AwPjBxMUKwJI1qdg>? NFnNTpdqdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhTkGNLDDTdoMh[W6mIFHreC=> NULSUnVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
HMEC-1  NGHCVJZHfW6ldHnvckBCe3OjeR?= MmDYNlAwPDBxNkCg{txoN22u NGO0VpFqdmirYnn0d{BHSUtiYX7kJHNz[8Li MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
G44 NHXPfllCeG:ydH;zbZMhSXO|YYm= M{G4flEwPS93MDFOwIcwdWx? M1vNeFI1KGh? M1PW[4lv\HWlZYOgZZBweHSxc3nz MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
G28 MX7BdI9xfG:|aYOgRZN{[Xl? MXqxM|UwPTBizsznM41t NXHVWXpROjRiaB?= MmfBbY5lfWOnczDhdI9xfG:|aYO= Ml;UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
G44 NFXvS4FRem:uaX\ldoF1cW:wIFHzd4F6 M123cVEwPS93MDFOwIcwdWx? NHf4cWczPC92OD:3NkBp M2\WSYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NFuxR4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
G28 MYLQdo9tcW[ncnH0bY9vKEG|c3H5 NFzDS3gyNzVxNUCg{txoN22u MUOyOE81QC95MjDo NH3nXodqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NInHO4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
HMEC-1  M{HVN2Fxd3C2b4Ppd{BCe3OjeR?= MoLUNU82NzVyIN88[{9udA>? M33kSlI1KGh? M{XKcolv\HWlZYOgZZBweHSxc3nz NXr3c4RYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
HMEC-1  MXvQdo9tcW[ncnH0bY9vKEG|c3H5 NYPweIJoOS93L{WwJO69\y:vbB?= MXWyOE81QC95MjDo NHL0UYlqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
HMEC-1  NF3jdoNHfW6ldHnvckBCe3OjeR?= M3HU[VEwPS93MDFOwIcwdWx? MlHSNlQhcA>? MlvQbY5lfWOnczDhJIRwe2ViZHXw[Y5l\W62IHTleIFkcG2nboVCpC=> NHHRT2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
LNT-229  NITqSZRHfW6ldHnvckBCe3OjeR?= NWf0eJVyOC5zL{GvNVAh|ryP NHPkeFMzPCCq MV7pcZBicXK|IITo[UBi\Ginc3nvckBw\iClZXzsd{B1dyC4aYTyc45m[3SrbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= Mn;DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkGxO|EoRjF7MkKxNVcyRC:jPh?=
T98G M1;4V2Z2dmO2aX;uJGF{e2G7 M2q3VlAvOS9zL{GwJO69VQ>? MVWyOEBp MVjpcZBicXK|IITo[UBi\Ginc3nvckBw\iClZXzsd{B1dyC4aYTyc45m[3SrbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NG\XTIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNVE4OSd-MUmyNlEyPzF:L3G+
LN-18 MVLGeY5kfGmxbjDBd5NigQ>? M{fSOFAvOS9zL{GwJO69VQ>? NHn2e5EzPCCq NWHKOXNXcW2yYXnyd{B1cGViYXTo[ZNqd25ib3[gZ4VtdHNidH:geol1em:wZXP0bY4hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ{MUG3NUc,OTl{MkGxO|E9N2F-
LN-308 M3HuT2Z2dmO2aX;uJGF{e2G7 M2LsPVAvOS9zL{GwJO69VQ>? NH;ac4szPCCq MV\pcZBicXK|IITo[UBi\Ginc3nvckBw\iClZXzsd{B1dyC4aYTyc45m[3SrbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NYfQOoprRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyNlEyPzFpPkG5NlIyOTdzPD;hQi=>
U87MG NFPxSm1HfW6ldHnvckBCe3OjeR?= NGPT[4sxNjFxMT:xNEDPxE1? MXOyOEBp MWjpcZBicXK|IITo[UBi\Ginc3nvckBw\iClZXzsd{B1dyC4aYTyc45m[3SrbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M2XDXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkKxNVcyLz5zOUKyNVE4OTxxYU6=
U87  MXXGeY5kfGmxbjDBd5NigQ>? MojJNE0zPSEQvHevcWw> NIjubmEyOiCqwrC= MkLrbY5lfWOnczDheZRweGijZ4mg[I9{\SCmZYDlcoRmdnSueR?= NGnKUWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe4PFM1Oyd-MkG3PFg{PDN:L3G+
U251 MlWySpVv[3Srb36gRZN{[Xl? MmrONE0zPSEQvHevcWw> NEPWZZoyOiCqwrC= MkfBbY5lfWOnczDheZRweGijZ4mg[I9{\SCmZYDlcoRmdnSueR?= M162RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N|Q{Lz5{MUe4PFM1OzxxYU6=
U87  M3nl[mFxd3C2b4Ppd{BCe3OjeR?= NGjR[JozPSEQvHevcWw> NU\tRXhLOjRxNEigbC=> MmXzbY5lfWOnczDhdI9xfG:|aYOgZZQhPDhiaDDzbYdvcW[rY3HueIx6 NX3S[|hSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PFg{PDNpPkKxO|g5OzR|PD;hQi=>
U251 NHnUTFBCeG:ydH;zbZMhSXO|YYm= NEnXdJgzPSEQvHevcWw> NX[0[G5nOjRxNEigbC=> NYnmPJNIcW6mdXPld{BieG:ydH;zbZMh[XRiNEigbEB{cWewaX\pZ4FvfGy7 NXTuOVFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PFg{PDNpPkKxO|g5OzR|PD;hQi=>
U87  M{i5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlqxNE0zPSEQvHevcWw> NXvGZploOC12ODDo NXjCVmYycW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz M3\oPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N|Q{Lz5{MUe4PFM1OzxxYU6=
U251 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDKNE0zPSEQvHevcWw> MX6wMVQ5KGh? MWjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NF;2epI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe4PFM1Oyd-MkG3PFg{PDN:L3G+
U251MG MoG2RZBweHSxc3nzJGF{e2G7 NEPSXXUyKML3TR?= NI\0fFQ1QCCq NHHjWGVqdmS3Y3XzJIFxd3C2b4Ppdy=> M2HPNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{W0PFA4Lz5{M{O1OFgxPzxxYU6=
U87MG M4PwbmFxd3C2b4Ppd{BCe3OjeR?= NYPBZ4o6OSEEtV2= M1jGPVQ5KGh? NHTVXWNqdmS3Y3XzJIFxd3C2b4Ppdy=> NGLFVHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O1OFgxPyd-MkOzOVQ5ODd:L3G+
U251MG NVWwd4NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVywMVI2KM7:TR?= M4fyOVI1NzR6IHi= NEntdolqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> M2rKc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{W0PFA4Lz5{M{O1OFgxPzxxYU6=
U87MG NVixbXlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XnUVAuOjVizszN MnrENlQwPDhiaB?= NIO2SG5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> M2r1O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{W0PFA4Lz5{M{O1OFgxPzxxYU6=
MCF-7  Mke5RZBweHSxc3nzJGF{e2G7 M1mzdVAuOjBizszN M1vGeVQ5KGh? NYTuW|J2cW6mdXPld{BieG:ydH;zbZM> M4HPSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUWzNVAzLz5{NEG1N|ExOjxxYU6=
T-47D MUfBdI9xfG:|aYOgRZN{[Xl? NHTNcGwxNTJyIN88US=> NU[1fYN5PDhiaB?= Mk[ybY5lfWOnczDhdI9xfG:|aYO= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF3M{GwNkc,OjRzNUOxNFI9N2F-
MCF-7  NHXTUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPzcod3OC1{MDFOwG0> MWO5OkBp NEDXSJJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NUi4fllSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVMyODJpPkK0NVU{OTB{PD;hQi=>
T-47D Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOwMVIxKM7:TR?= MVK5OkBp MY\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MnPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUOxNFIoRjJ2MUWzNVAzRC:jPh?=
FaDu  MkDsRZBweHSxc3nzJGF{e2G7 NFXJPJkzPcLiwsXNxsA> MXu0POKhcMLi Mo\FbY5lfWOnczDhdI9xfG:|aYO= MlrtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NUewOVYoRjJ2NUW3NFU3RC:jPh?=
CAL27 NV7qUmJvSXCxcITvd4l{KEG|c3H5 MYOyOeKhyrWPwrC= NYnDPJRwPDkEoHlCpC=> NHXVVY5qdmS3Y3XzJIFxd3C2b4Ppdy=> Mne5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NUewOVYoRjJ2NUW3NFU3RC:jPh?=
SCC25 M3nXdmFxd3C2b4Ppd{BCe3OjeR?= NV\IT|htOjYEoNM1UeKh NIHFTIU1QMLiaNMg M2H4fIlv\HWlZYOgZZBweHSxc3nz MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3N{C1Okc,OjR3NUewOVY9N2F-
FaDu  MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HidFYvOjYkgKOyNFDDqML3TR?= M{PkSVczKGh? NWrNWlFWemW|dXz0d{Bud2SncnH0[Uwh\G:|ZT3k[ZBmdmSnboSg[5Jwf3SqIHnubIljcXSrb36= MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3N{C1Okc,OjR3NUewOVY9N2F-
CAL27 MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDzeVNPPi5{NfMAl|IxOMLiwsXN NYfhV5ZWPzJiaB?= NIfISG5z\XO3bITzJI1w\GW{YYTlMEBld3OnLXTldIVv\GWwdDDndo94fGhiaX7obYJqfGmxbh?= NWXEOYJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVcxPTZpPkK0OVU4ODV4PD;hQi=>
SCC25 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofROk4zPeLCk{KwNOKhyrWP NF;Fbmk4OiCq NGrMT2Vz\XO3bITzJI1w\GW{YYTlMEBld3OnLXTldIVv\GWwdDDndo94fGhiaX7obYJqfGmxbh?= NUPFfppCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVcxPTZpPkK0OVU4ODV4PD;hQi=>
H28 NHPDSoJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHjFPY4yKG6PLUKwNEDPxE1? NXPuOXFtPzJiaB?= M1Hqe4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NHXHfYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5OVI4PCd-MkS1PVUzPzR:L3G+
MM05 MlPKR4VtdCCYaXHibYxqfHliQYPzZZk> M3PSeVEhdk1vMkCwJO69VQ>? MoPqO|IhcA>? M3fGVoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NGPaZVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5OVI4PCd-MkS1PVUzPzR:L3G+
MSTO-211H NFPZPYZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{XkOFEhdk1vMkCwJO69VQ>? Ml73O|IhcA>? NXjkVYNn\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV7NUK3OEc,OjR3OUWyO|Q9N2F-
REN M2jWXGNmdGxiVnnhZoltcXS7IFHzd4F6 NHXPc3IyKG6PLUKwNEDPxE1? NXrwSph1PzJiaB?= Mnvp[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M2q1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUm1Nlc1Lz5{NEW5OVI4PDxxYU6=
LN-308  M1TnfGZ2dmO2aX;uJGF{e2G7 MXWxNQKBkc7:bR?= M1LyOlI1KGh? NIHqUHhFVVORwrC= NGO1dXJz\WS3Y3XzJGFpWiCycn;0[YlvKGyndnXsd{BidmRiRGLFJJJmeG:{dHXyJIFkfGm4aYT5 M4ewOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUCwNFU3Lz5{NkWwNFA2PjxxYU6=
HaCaT  M3r4WmZ2dmO2aX;uJGF{e2G7 NEHvOowyOOLCid88cS=> M2C3PFQ5KGh? NVHKWmRiTE2VT9Mg MmK1doVlfWOnczDUS2Yu|rJ{wrDtVm5CKGW6cILld5Nqd25? NITiPGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWwNFA2Pid-Mk[1NFAxPTZ:L3G+
S-24 M4DzdWZ2dmO2aX;uJGF{e2G7 NHezR4wyNzFy4pEJ{txu MWKyOEBp Mmm4SG1UV8Li NGTLbHJz\WS3Y3XzJGRTTSC{ZYDvdpRmeiCjY4Tpeol1gQ>? NWXHdXhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NFAxPTZpPkK2OVAxODV4PD;hQi=>
ZH-161 MXXGeY5kfGmxbjDBd5NigQ>? MXyxM|Ex6oDLzszt MlvaNlQhcA>? NVLL[Yp4TE2VT9Mg M3z4NpJm\HWlZYOgSHJGKHKncH;yeIVzKGGldHn2bZR6 Mkm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3MECwOVYoRjJ4NUCwNFU3RC:jPh?=
LN-308  MkPESpVv[3Srb36gRZN{[Xl? M2[zV|EwOTBxMUCw5qCK|ryv NHPNd4wzPCCq MYrEUXNQyqB? MXzy[YR2[2W|IFTSSUBz\XCxcoTldkBi[3Srdnn0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NUfKXWY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NFAxPTZpPkK2OVAxODV4PD;hQi=>
M21 NVLF[WFuTnWwY4Tpc44h[XO|YYm= M{X2V|EhcHJ? MV7CbY5lcW6pIHHm[olvcXS7IITvJIlvfGWpcnnuJIFteGijdj;i[ZRiOyCqZYTldo9lcW2ncjDpckBpfW2jbjDNNlEh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDpcpRm\3Krbj3t[YRq[XSnZDDoeY1idiCPMkGgZ4VtdCCjZHjld4lwdiC2bzD2bZRzd26nY4TpckBi\nSncjCxJIhzKGmwIIDy[ZNmdmOnIH;mJG1vS2x{LDDJR|UxKD1iMD6wNFA1KM7:TT6= M3HUfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{WzPFE1Lz5{Nke1N|gyPDxxYU6=
HEK293T MWLGeY5kfGmxbjDhd5NigQ>? M3jDSlIhcHK| MmKxRolv\GmwZzDh[oZqdmm2eTD0c{B{d2y3YnzlJJRzfW6lYYTl[EBpfW2jbjDy[YNwdWKrbnHueEBH[y22YXfn[YQh[WyyaHHWZoV1[TNiYX7kJIlvfGWpcnnud{B4\XKnIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy|IHHmeIVzKDJiaILzJIJ6KGOxbYDleIl1cW:wIFXMTXNCNWyra3WgZZN{[XluIFnDOVAhRSByLkCwNFUyKM7:TT6= NUj3O5lCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVUxQTZpPkK0NFk2ODl4PD;hQi=>
HT-29 NFXreoFHfW6ldHnvckBie3OjeR?= M{DLOlIhcHK| NIO0TndCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHnueIVoemmwIHHsdIhiXmKndHG1JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKEiWLUK5JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJIFlcGW|aX;uJJRwKH[rdILvcoVkfGmwIHHmeIVzKDJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUKg{txONg>? NXPNRnVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVE2QTRpPkK4N|UyPTl2PD;hQi=>
HEK293 M4\OXWZ2dmO2aX;uJIF{e2G7 NYSyWY02OiCqcoO= MkTXRY51[WexbnnzeEBi[3Srdnn0fUBifCCrboTl[5JqdiCjbIDoZXZj\XSjMzCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygZYRp\XOrb36geI8h\mmkcnnuc4dmdiCjZoTldkAzKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjJ{IN88UU4> NXTJUJZ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVE2QTRpPkK4N|UyPTl2PD;hQi=>
SKOV3 MVrGeY5kfGmxbjDhd5NigQ>? NX3aNJJCOiCqcoO= NWrX[HdbSW62YXfvcol{fCCjY4Tpeol1gSCjdDDpcpRm\3KrbjDhcJBp[V[kZYThN4FteGijVnLleIE2KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPLU3Y{KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKGGmaHXzbY9vKHSxIH\pZpJqdm:pZX6gZYZ1\XJiMjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMD6zO{DPxE1w MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MUW5OEc,Ojh|NUG1PVQ9N2F-
U87MG M32xZWZ2dmO2aX;uJIF{e2G7 M2LiOVExOCCwTR?= MmXuNlQhcHK| MoLCTY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMh[WOldX31cIF1cW:wIHH0JFExOCCwTTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JI1mfGixZB?= M3TQZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG MnvoSpVv[3Srb36gZZN{[Xl? MoXMNVAxKG6P MkHiNlQhcHK| Mo\oTY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMh[WOldX31cIF1cW:wIHH0JFExOCCwTTDh[pRmeiB{NDDodpMhcW5icILld4Vv[2Vib3[gUWROOiCrbnjpZol1d3JiboX0cIlvNTNiYomgW4V{fGW{bjDicI91KG2ndHjv[C=> M13IUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG NULTXop2TnWwY4Tpc44h[XO|YYm= NXXWNVhxOTByIH7N NF3UO4szPCCqcoO= MmKyTY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMh[WOldX31cIF1cW:wIHH0JFExOCCwTTDh[pRmeiB{NDDodpMhcW5icILld4Vv[2Vib3[gUWROOiCrbnjpZol1d3JiboX0cIlvNTNiYX7kJG1FVTRiaX7obYJqfG:{IGPKMVE4OjJ3NUCgZpkhX2W|dHXyckBjdG:2IH3leIhw\A>? MnHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N|A{RC:jPh?=
U87MG NXTTO4FoTnWwY4Tpc44h[XO|YYm= M2jvZlExOCCwTR?= MVW4JIhzew>? NGfheGFKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJG1FVTJibWLORUBmgHC{ZYPzbY9vKGG2IEGwNEBvVSCjZoTldkA5KGi{czDpckBxemW|ZX7j[UBw\iCPRF2yJIlvcGmkaYTvdkBvfXSuaX6tN{BidmRiTVTNOEBqdmirYnn0c5IhW0pvMUeyNlU2OCCkeTDSWE1RS1JibXX0bI9l NV7I[2Q6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG MonKSpVv[3Srb36gZZN{[Xl? M2XjRlExOCCwTR?= MV6yOEBpenN? MVjJcohq[mm2aX;uJI9nKGGucHjhWoJmfGF|IHnueIVoemmwIHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIGDVUWEhdVKQQTDlfJBz\XO|aX;uJIF1KDFyMDDuUUBi\nSncjCyOEBpenNiYomgVnQuWEOUIH3leIhw\A>? NYTpdVc4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG MmjVSpVv[3Srb36gZZN{[Xl? MlHYNVAxKG6P M3\KZ|I1KGi{cx?= MlHCTY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDQWW1CKG2UTlGg[ZhxemW|c3nvckBifCBzMECgcm0h[W[2ZYKgNlQhcHK|IHnuJJBz\XOnbnPlJI9nKE2GTUKgbY5pcWKrdH;yJI52fGyrbj2zJIJ6KFKWLWDDVkBu\XSqb3S= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG MWjGeY5kfGmxbjDhd5NigQ>? NFHvfVcyODBibl2= Ml23NlQhcHK| NYXuO3ltUW6qaXLpeIlwdiCxZjDhcJBp[V[kZYThN{BqdnSnZ4LpckBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBRXU2DIH3SUmEh\XiycnXzd4lwdiCjdDCxNFAhdk1iYX\0[ZIhOjRiaILzJIlvKHC{ZYPlcoNmKG:oIF3EUVQhcW6qaXLpeI9zKFOMLUG3NlI2PTBiYomgVnQuWEOUIH3leIhw\A>? M1rxd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG NGnyR21HfW6ldHnvckBie3OjeR?= NILTV4IyODBibl2= NWDD[4JpOjRiaILz MkHjTY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDQWW1CKG2UTlGg[ZhxemW|c3nvckBifCBzMECgcm0h[W[2ZYKgNlQhcHK|IHnuJJBz\XOnbnPlJI9nKE2GTUKgbY5pcWKrdH;yJI52fGyrbj2zJIFv\CCPRF20JIlvcGmkaYTvdkBUUi1zN{KyOVUxKGK7IGLUMXBEWiCvZYToc4Q> NHKxPZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG NILBfJBHfW6ldHnvckBie3OjeR?= M361WVExOCCwTR?= NI\DRpkzPCCqcoO= MX;Jcohq[mm2aX;uJI9nKGGucHjhWoJmfGF|IHnueIVoemmwIHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIICyNUBuWk6DIHX4dJJme3Orb36gZZQhOTByIH7NJIFnfGW{IEK0JIhzeyCkeTDSWE1RS1JibXX0bI9l NW\IbYJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG NInRcIxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MX2xNFAhdk1? MWC3NkBpenN? MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV6N13HJINmdGy|IHH0JFExOCCwTTDh[pRmeiB5MjDodpMhcW5icILld4Vv[2Vib3[gUWROOiCrbnjpZol1d3JiboX0cIlvNTNiYomgUXRUKGG|c3H5 NEPHVJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O|U{ODN:L3G+
U87MG M2n5fGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NWTpbZhqOTByIH7N MY[3NkBpenN? NGHLPJdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJIF1KDFyMDDuUUBi\nSncjC3NkBpenNiaX6gdJJme2WwY3Wgc4YhVUSPMjDpcohq[mm2b4KgcpV1dGmwLUOgZY5lKE2GTUSgbY5pcWKrdH;yJHNLNTF5MkK1OVAh[nliTWTTJIF{e2G7 Mkm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N|A{RC:jPh?=
U87MG MWTD[YxtKGO7Y3zlJIF{e2G7 NFrJcFQyODBibl2= MYiyOEBpenN? M2HYbmNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMD;HNUBxcGG|ZTDheEAyODBibl2gZYZ1\XJiMkSgbJJ{ M1S0eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=
U87MG M2HqbmFvfGlvaX72ZZNqfmViYYPzZZk> NHiwUWEyOCC3TR?= NFjTPGYzPCCqcoO= NFvIOGVCdnSrLXnueoF{cX[nIHHjeIl3cXS7IHnuJIh2dWGwIGW4O21IKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEK0JIhzeyCkeTD0doFve3enbHygZZN{[Xl? NX7wUlBXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U{ODNpPkK5O|c2OzB|PD;hQi=>
U87MG MkW4RY51cS2rbo\hd4l3\SCjc4PhfS=> MU[xNEB2VQ>? NVrXVoJVOjRiaILz NF:5OXdCdnSrLXnueoF{cX[nIHHjeIl3cXS7IHnuJIh2dWGwIGW4O21IKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEK0JIhzeyCrbjDwdoV{\W6lZTDv[kBOTE1{IHnubIljcXSxcjDueZRtcW5vMzDhcoQhVUSPNDDpcohq[mm2b4KgV2ouOTd{MkW1NEBjgSC2cnHud5dmdGxiYYPzZZk> M4Oy[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N|A{Lz5{OUe3OVMxOzxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pFAK / p-AKT ; 

PubMed: 19114005     


G28 cells were treated with 50 μg/ml cilengitide for 30, 60 and 120 minutes at 37°C. Cell lysates containing similar amounts of protein were separated by SDS-PAGE, transferred to a nitrocellulose membrane and probed with specific antibodies for detection of β-actin and phosphorylated FAK and Akt.

GLI1; 

PubMed: 31366904     


Western blottingting showing downregulated GLI1 with Integrin αvβ3 inhibitor Cilengitide and upregulated GLI1 with co-stimulator ligand RGD compared to the blank control in SGC7901 MCAs and BGC823 MCAs. 

19114005 31366904
Immunofluorescence
VE-cadherin / β3 integrin ; 

PubMed: 19212436     


Confluent HUVEC plated on fibronectin or collagen I were exposed to cilengitide (10 µM each) for the indicated time and double stained for VE-cadherin and β3 integrin. Cilengitide disrupted VE-cadherin staining and promoted appearance of β3 at VE-cadherin-depleted cell-cell borders. Higher magnification of HUVEC cultures demonstrate rare co-localization of VE-cadherin and β3 integrin at cellular junctions upon cilengitide stimulation (arrowheads). Bars: 10 µm.

19212436
Growth inhibition assay
Cell number ; 

PubMed: 24153102     


Cell detachment following 1 hr Cilengitide treatment. Cells were treated with cilengitide for 1 hr, washed with PBS, and remaining attached cells were trypsinized and counted. A) T-47D cells showed a strong dose response, with almost complete cell detachment at 20 uM cilengitide treatment. B) MCF-7 cells showed moderate cell detachment similar to C) MDA-MB-231 cells. D) MDA-MB-468 cells showed little to no cell detachment following this short exposure to cilengitide. Figures show Mean ± SEM and represent the average of three experiments. * = ≤ 0.05.

24153102
体内研究 Cilengitide单独处理,有效对抗肿瘤生长和血管生成。100 μg Cilengitide处理肿瘤,与对照组相比,显著降低CD31+血管数。100 μg Cilengitide处理动物大脑中的肿瘤,与接收无效肽处理的相比,促进细胞凋亡。Cilengitide 处理携带黑色素移植瘤M21的小鼠,对照组相比,延长小鼠寿命,分别为36.5 天vs 17.3天。[5]Cilengitide 可以增加细胞毒性药物相关联的治疗的益处,包括对肿瘤模型的化疗和放射治疗。Cilengitide (250 mg/dose)单独处理小鼠,与未经处理的小鼠相比,没有改变乳腺癌移植瘤的肿瘤生长,但与RIT(CMRIT)联合治疗,使用RIT和六种剂量的Cilengitide (250 mg/dose)增加治疗的疗效,小鼠的治愈率从只用RIT处理的 15%提高到53%。CMRIT处理内皮细胞5天,显著促进肿瘤细胞凋亡,且降低肿瘤细胞增殖。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[2]
- 合并

整合素竞争结合实验:

固定化重组可溶性的整合素,同时加入在Tris 缓冲生理盐水(TBS++) (0.1% (w/v) BSA, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2 10 μM MnCl2, 20 mM Tris-HCl; pH 7.4)中连续稀释的肽,及生物素化的Vitronectin(1μg/mL)。在37°C下温育3小时后,使用Tris 缓冲生理盐水洗涤,通过与抗生物素的碱性磷酸酶联合的抗体温育,再经对硝基苯基磷酸酶底物显影,测定结合的配体。加入NaOH终止反应,在405 nm处读取彩色信号强度。
细胞实验:[3]
- 合并
  • Cell lines: 人体微血管内皮细胞系HMEC-1
  • Concentrations: 1-50 μg/mL
  • Incubation Time: 3 天
  • Method: HMEC-1 按每孔1×104个接种在未包被的48孔板中,在含4% FCS 及 Cilengitide的培养基中温育。在37°C下温育72小时, 用胰蛋白酶处理细胞并计数。
    (Only for Reference)
动物实验:[5]
- 合并
  • Animal Models: 携带人体胶质母细胞瘤移植瘤U87 MG的小鼠
  • Dosages: 100μg
  • Administration: 每天腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (142.31 mM)
Water 8 mg/mL (11.38 mM)
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 702.68
化学式

C29H41F3N8O9

CAS号 199807-35-7
储存条件 粉状
溶于溶剂
别名 EMD 121974, NSC 707544

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01517776 Terminated Drug: Cilengitide|Drug: Temozolomide Gliomas Martin-Luther-Universität Halle-Wittenberg|Merck KGaA Darmstadt Germany January 2012 Phase 2
NCT01118676 Completed Drug: cilengitide radiochemotherapy Locally Advanced Non Small Cell Lung Cancer (NSCLC)* Institut Claudius Regaud|Merck KGaA Darmstadt Germany March 2010 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    The recommend vehicle is 30% propylene glycol, 5% Tween 80, 65% D5W at 30mg/ml, can you let me know if this is a suspension or clear solution?

  • 回答:

    S7077 Cilengitide can be dissolved in 30% propylene glycol/5% Tween 80/65% D5W at 10 mg/ml as a clear solution.

  • 问题 2:

    Is Cilengitide a TFA salt?

  • 回答:

    S7077 Cilengitide is actually a TFA salt, and the ratio between Cilengitide and TFA is 1:1.

Integrin Signaling Pathway Map

Tags: 购买Cilengitide trifluoroacetate | Cilengitide trifluoroacetate供应商 | 采购Cilengitide trifluoroacetate | Cilengitide trifluoroacetate价格 | Cilengitide trifluoroacetate生产 | 订购Cilengitide trifluoroacetate | Cilengitide trifluoroacetate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID